We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BASE
2901
DELISTED
Couchbase
BASE
| $208K | ﹤0.01% |
+6,697
| New | +$246K |
|
2902
Monte Rosa Therapeutics
GLUE
$1.35B
| $206K | ﹤0.01% |
+9,233
| New | +$265K |
|
|
DS
2903
DELISTED
Drive Shack Inc.
DS
| $206K | ﹤0.01% |
73,199
+2,514
| +4% | +$6.77K |
|
|
DZSI
2904
DELISTED
DZS Inc. Common Stock
DZSI
| $206K | ﹤0.01% |
16,809
+416
| +3% | +$6.54K |
|
2905
Mustang Bio
MBIO
$4.55M
| $205K | ﹤0.01% |
102
+3
| +3% | +$6.44K |
|
|
KG
2906
Kestrel Group
KG
$69M
| $205K | ﹤0.01% |
3,247
+10
| +0.3% | +$655 |
|
2907
Nathan's Famous
NATH
$402M
| $205K | ﹤0.01% |
3,348
+20
| +0.6% | +$1.32K |
|
2908
CorMedix
CRMD
$584M
| $202K | ﹤0.01% |
43,356
+317
| +0.7% | +$1.85K |
|
2909
Tonix Pharmaceuticals
TNXP
$192M
| $202K | ﹤0.01% |
1
| – | – |
|
|
NVO
2910
Novo Nordisk
NVO
$209B
| $201K | ﹤0.01% |
+4,180
| New | +$202K |
|
|
NMTR
2911
DELISTED
9 Meters Biopharma
NMTR
| $201K | ﹤0.01% |
7,724
+500
| +7% | +$11.8K |
|
2912
ARS Pharmaceuticals
SPRY
$612M
| $200K | ﹤0.01% |
20,013
+3,333
| +20% | +$82.2K |
|
2913
Fortress Biotech
FBIO
$88.7M
| $195K | ﹤0.01% |
4,041
+164
| +4% | +$8.01K |
|
2914
Full House Resorts
FLL
$89M
| $195K | ﹤0.01% |
18,336
+1,164
| +7% | +$9.94K |
|
|
TRVN
2915
DELISTED
Trevena, Inc.
TRVN
| $195K | ﹤0.01% |
253
+8
| +3% | +$6.78K |
|
|
AHT
2916
Ashford Hospitality Trust
AHT
$21M
| $194K | ﹤0.01% |
1,317
+159
| +14% | +$26.9K |
|
|
LENZ
2917
LENZ Therapeutics
LENZ
$168M
| $193K | ﹤0.01% |
+1,678
| New | +$248K |
|
|
ITI
2918
DELISTED
Iteris, Inc.
ITI
| $193K | ﹤0.01% |
36,467
+311
| +0.9% | +$1.82K |
|
|
TAST
2919
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $189K | ﹤0.01% |
51,509
+801
| +2% | +$3.58K |
|
2920
Wave Life Sciences
WVE
$1.2B
| $182K | ﹤0.01% |
37,050
+2,670
| +8% | +$16.2K |
|
2921
Dianthus Therapeutics
DNTH
$6.09B
| $180K | ﹤0.01% |
1,547
-127
| -8% | -$14.8K |
|
2922
Solid Biosciences
SLDB
$900M
| $178K | ﹤0.01% |
4,974
+112
| +2% | +$4.76K |
|
2923
Harvard Bioscience
HBIO
$29.2M
| $177K | ﹤0.01% |
2,531
+180
| +8% | +$14.3K |
|
|
CSLT
2924
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $177K | ﹤0.01% |
112,933
+3,480
| +3% | +$6.82K |
|
2925
Aterian
ATER
$5.37M
| $175K | ﹤0.01% |
1,346
+103
| +8% | +$11.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.